Global Scans · Diet Drugs · Weekly Summary

• [New] Patent protection for semaglutide will remain in place in the US and Europe into the 2030s. Chemistry World
• [New] GLP-1 Medicare and Medicaid coverage will begin in 2026 through a pilot program called the GLP-1 bridge. Ritter Insurance Marketing
• [New] President Trump's GENEROUS model and GLP-1 bridge could make major strides for making GLP-1 medications more affordable for many. Ritter Insurance Marketing
• [New] Under the GLP-1 Bridge Program, Medicare will cover Wegovy specifically for weight loss - not just for diabetes management. Pound of Cure Weight Loss
• [New] The final driver in ADM's snack analysis spotlights emerging innovation opportunities from users of anti-obesity medications such as GLP-1. CNS Media
• If Congress acts to expand permanent Medicare coverage of GLP-1 drugs for obesity, the coverage picture after 2027 could change. Medical Daily
• The Centers for Disease Control and Prevention recommends drinking two to four glasses of fluids each hour for prevention of heat-related illness, a goal that might be harder to achieve for patients on a GLP-1. ABC News
• 6% of large employers dropped GLP-1 obesity coverage in 2026, and another 5% are planning to or are actively considering it in 2027. Resourceful Finance Pro
• The new Medicare GLP-1 Bridge program will allow eligible Medicare beneficiaries to get certain weight-loss GLP-1 medications, including the Wegovy injection and pill, for $50 a month. Noom: Lose weight and keep it off.
• A large-scale trial has been launched, with $100 million in backing, to explore whether lifestyle changes coupled with GLP-1 agonists or similar incretin therapies can reduce the risk of dementia. Pharmaphorum
• FDA approves Ozempic for a new indication: reducing the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. GoalBMI Wellness
• FDA approves Rybelsus, the first oral semaglutide tablet for type 2 diabetes management - proving that the GLP-1 mechanism could be effective in pill form and setting up the later oral Wegovy development. GoalBMI Wellness
• As of 2025, approximately 10 million individuals in the US used GLP-1 medications - a number expected to significantly increase through 2026 and 2027 as pricing becomes more accessible and awareness continues to grow. GoalBMI Wellness
• Foodology has identified GLP-1 - driven eating patterns as one of seven trends expected to shape F & B development in 2026, alongside digestive health, clean label, flavour complexity, supply chain disruption, functional foods, and technology-enabled innovation. CNS Media
• Globally, the July Medicare GLP-1 bridge will be the next major commercial readout for Novo and Lilly. Blogs on Markets
• Udi Alroy, CEO and co-founder of CarobWay, expects GLP-1 companion nutrition to rapidly evolve from a trending talking point into a major commercial imperative over the next 12 to 18 months. CNS Media
• Until the patent for semaglutide expires in 2032, anything being sold as generic semaglutide in the US is going to be unregulated or illegal. Treated
• Telehealth providers like Hims and Hers could soon see more business, now that more and more employees are losing insurance coverage for weight loss drugs like Wegovy and Zepbound. Scripps News
• Tirzepatide alone is forecast to be worth more than $70 billion, the biggest drug ever. LinkedIn
• The Group Insurance Commission, the state agency that provides benefits to public employees in Massachusetts, plans to stop covering GLP-1 weight loss drugs. Wbur

Last updated: 08 August 2026